M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Lilly's Lartruvo has been a key launch for its oncology business, but thanks to a phase 3 fail, it plans to stop promoting the drug.
A small piece of a campus in New York that was once owned by Wyeth and then Pfizer will now become home to a small drugmaker.
A Sun distributor allegedly inked transactions worth $816 million with a firm controlled by Sun’s co-promoter Sudhir Valia.
Troubles continue to pile up for Immunomedics which has now received a complete response letter for candidate for breast cancer.
A close look at SEC documents describing Lilly's bid for Loxo indicates more interest in targeted oncology than the deal's genesis might indicate,…
NICE initially told Eli Lilly that its breast cancer drug Verzenio wasn't cost-effective. So Lilly dished up a price break—and it worked.
Spectrum is offloading seven drugs and transferring 40% of its total workforce to Aurobindo in a deal to "laser-focus" on novel cancer drugs.
Adamis' partner Sandoz is launching the prefilled syringe at a 16.5% discount to Mylan’s authorized generic EpiPen and Teva’s generic version.
Teva has reaped plenty of tax benefits from its home country in recent years. But now the Israeli government reportedly wants some of that money back.
If you thought Amgen osteoporosis candidate Evenity was down for the count, think again.